Vigonvita Life Sciences Co., Ltd. (VIGONVITA-B) has filed its Monthly Return on Movements in Securities for the period ended 31 May 2026 with Hong Kong Exchanges and Clearing Limited, confirming a steady capital structure and full compliance with public-float rules.

The company’s authorised share capital remained at 167.60 million ordinary shares with a par value of RMB1 each. This comprises: • 66.68 million H-shares listed in Hong Kong. • 100.92 million unlisted domestic shares.

Issued share capital was unchanged during the month: 66.68 million H-shares and 100.92 million unlisted shares, with no treasury shares outstanding. Vigonvita also affirmed that its H-share public float comfortably meets the Main Board’s minimum 25% requirement.

No share options, warrants, convertible securities or other equity-linked instruments were issued, exercised or cancelled in May, and there were no repurchases or other share movements. The company reported no Hong Kong Depositary Receipts.

All requisite confirmations—including receipt of all consideration, fulfilment of listing conditions and regulatory filings—were provided by Board Secretary and Joint Company Secretary Guo Ting in the 4 June 2026 submission.